Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
March 06, 2019 16:10 ET
|
Xeris Pharmaceuticals, Inc.
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 01, 2019 16:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
February 20, 2019 07:30 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
February 13, 2019 19:26 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
February 11, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
November 07, 2018 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Glucagon pen NDA accepted for review by FDA Continuing to execute commercial build and launch readiness for glucagon pen Advancing pipeline of preclinical and clinical development-stage products...
Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights
August 13, 2018 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Successfully Completed Initial Public Offering (IPO) Submitted New Drug Application (NDA) for Glucagon Rescue Pen CHICAGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq:...
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
July 31, 2018 07:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 31, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team
July 30, 2018 07:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 30, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 26, 2018 16:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, June 26, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...